DrugPatentWatch Database Preview
TALZENNA Drug Profile
Email this page to a colleague
When do Talzenna patents expire, and when can generic versions of Talzenna launch?
Talzenna is a drug marketed by Pfizer and is included in one NDA. There are five patents protecting this drug.
This drug has eighty-seven patent family members in thirty countries.
The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.
DrugPatentWatch® Generic Entry Outlook for Talzenna
Talzenna will be eligible for patent challenges on October 16, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 20, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TALZENNA
| International Patents: | 87 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Clinical Trials: | 18 |
| Patent Applications: | 503 |
| Drug Prices: | Drug price information for TALZENNA |
| What excipients (inactive ingredients) are in TALZENNA? | TALZENNA excipients list |
| DailyMed Link: | TALZENNA at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TALZENNA
Generic Entry Date for TALZENNA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TALZENNA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Epizyme, Inc. | Phase 1 |
| Bryan Schneider, MD | Phase 2 |
| Foundation Medicine | Phase 2 |
Pharmacology for TALZENNA
| Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
| Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
US Patents and Regulatory Information for TALZENNA
International Patents for TALZENNA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2814581 | Try Before You Buy |
| Denmark | 2630146 | Try Before You Buy |
| Japan | 2018012698 | Try Before You Buy |
| Slovenia | 2630146 | Try Before You Buy |
| Poland | 2630146 | Try Before You Buy |
| Japan | 2017061526 | Try Before You Buy |
| South Korea | 20140009181 | Try Before You Buy |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TALZENNA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2767537 | 1990055-4 | Sweden | Try Before You Buy | PRODUCT NAME: TALAZOPARIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1377 20190624 |
| 2767537 | 19C1071 | France | Try Before You Buy | PRODUCT NAME: TALAZOPARIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1377 20190624 |
| 2767537 | PA2019522,C2767537 | Lithuania | Try Before You Buy | PRODUCT NAME: TALAZOPARIBAS; REGISTRATION NO/DATE: EU/1/19/1377 20190620 |
| 2767537 | CR 2019 00055 | Denmark | Try Before You Buy | PRODUCT NAME: TALAZOPARIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT; REG. NO/DATE: EU/1/19/1377 20190624 |
| 2767537 | C201930072 | Spain | Try Before You Buy | PRODUCT NAME: TALAZOPARIB, OPCIONALMENTE EN FORMA DE SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1377; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1377; DATE OF FIRST AUTHORISATION IN EEA: 20190620 |
| 2767537 | LUC00140 | Luxembourg | Try Before You Buy | PRODUCT NAME: TALAZOPARIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/19/1377 20190624 |
| 2767537 | PA2019522 | Lithuania | Try Before You Buy | PRODUCT NAME: TALAZOPARIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/19/1377 20190620 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
